Trial abstract · §2
SELANK-RU-ANXIETY — design and population
Design, allocation, arms and the population enrolled.
§2Design and population
§2.1Design and allocation
- Design class
- Observational cohort analysis
- Masking
- Not applicable
- Arms
- 2
- Allocation
- Randomised between the intervention and its comparator
- Endpoint adjudication
- Not applicable to the primary endpoint of this design
- Data monitoring
- As specified in the protocol
§2.2Arms
Table 2. Randomised arms. Illustrative: arm-level allocations are reconstructed by the Institute from the design class and the randomised total where the published report does not state them.
| Arm | Allocated | Share | Description |
|---|---|---|---|
| Selank | — | — | Intervention at the dose reached after titration |
| Placebo | — | — | Matched placebo, administered on the same schedule |
| The randomised total is not recorded by the Institute and arm-level figures are therefore not presented. | |||
§2.3Population
Indication. Cognitive performance and neuroprotection
Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
Geographic footprint. Poland.
§2.4Eligibility as the Institute reads it
- Included. Domain-specific cognitive function or protection against cognitive decline, assessed by standardised neuropsychological batteries or clinical dementia rating.
- Excluded. Participants for whom the intervention is contraindicated, including as stated in the russian labelling. Exclusion criteria narrow the population to which the estimate applies and are the principal source of indirectness where a trial estimate is applied to ordinary practice.
Compound Evidence Institute · CEI-TR-0126/2 · https://compoundevidence.com/trials/selank-ru-anxiety/design/ · retrieved 30 July 2026